Clinical trials simplified.

Therapeutic innovations expedited.
Risks mitigated. An unrivaled, patented platform of advisory and technology for military-sponsored Clinical Trial Center study leaders.

About Us

JusGlobal GOV is an unprecedented achievement in clinical trial innovation created and developed by Founder, Chairman & CEO Beatrice O’Brien.Mrs. O’Brien has assembled the most qualified clinical experts, medical investigators, scientific researchers, management consultants, product developers, legal and regulatory professionals to introduce a comprehensive, support-driven platform that streamlines and optimizes the entire pre-clinical and clinical phases of investigatory research trials conducted at military clinical trial centers.

The unparalleled strength of the JusGlobal expert team lies at the intersection of their remarkable professional accomplishments that traverse the entire spectrum of clinical experience, resource allocation, scientific and academic inquiry, drug development and manufacturing, quality control and legal and regulatory advisory. These highly credentialed experts deliver and support a never-before-seen patented innovation that re-engineers the entire clinical investigatory process for advanced agility, speed, safety, efficiency, transparency and security.
Only JusGlobal GOV is eminently qualified to deliver clinical and pharmacological guidance and support on an interactive yet highly secure technology platform. Along with our accomplished advisory board members, who are legal, healthcare, business strategy and marketing experts, our team has over 100 years of combined professional experience. For military researchers managing multi-site investigatory studies and clinicians in various armed services branches, JusGlobal GOV delivers a unifying architecture that streamlines yet elevates qualitative controls, facilitating transparency, enabling self-reporting of symptoms for study subjects and simplifying a formerly complex and arcane research landscape.
For Government Researchers
From the initial application through the complex and vulnerable pre-clinical stage that determines if and for what indication a potential drug or device should be evaluated to the clinical trial phases and FDA approval, JusGlobal GOV brings previously unforeseen efficiency to the process of introducing new therapies to the marketplace while accelerating quality control and mitigating study risks throughout the trials process. The result is improved study accuracy and safety that becomes a pathway to speed new medications to market, improving global health by advancing interventive and curative therapies.
JusGlobal GOV is a dynamic more than a network on which clinical trial information can be recorded, reviewed and exchanged through proprietary communications channels. It is a highly secure platform that delivers a 24/7 real time at-a-glance accuracy and simplicity. Further, JusGlobal GOV facilitates text/voice/video communication and digital voice signing through a blockchain conduit between researchers and volunteer participants.

JusGlobal GOV delivers a team of experts to support, guide and advise at every aspect of clinical investigation. Our professional are authorities in the clinical and regulatory fields who assist government researchers in evaluating and verifying study documents and directing resources while advancing safety, accuracy and quality.

JusGlobal GOV has an ably qualified support team with industry-specific experience to analyze potential threats, assess risks and facilitate safety and advanced communication in clinical trial research. We identify challenges before they go undetected, potentially disrupting a study and resulting in costly delays, which are now common to 85 percent of all clinical trials and typically cost $600,000 to $8 million a day for a large scale study.

JusGlobal Pharma provides actionable insights to that empower researchers, executives and investors to maintain confidence in their capital and resource investment in a trial.

We also provide a transparent Open Forum for all parties to ask and answer questions related to a clinical trial, creating an environment of trust for all parties.

Learn More

JusGlobal Pharma speeds time to market while mitigating risk and adding an unprecedented degree of transparency. It’s a secure, permissions-based application with desktop and mobile support that provides fail-proof guidance for every need and communication. JusPharma identifies the expertise required for the pre-clinical, clinical and post-clinical aspects of a trial, tracking every single element on an agile yet secure platform.

Get Started

Sign Up

For Contract Research Organizations (CROs)
Acontract research organization can attract more clients by empowering the JusGlobal Pharma platform to be its competitive edge. Imagine improving, accuracy, safety and speed to market for client sponsors that outsource the clinical investigation process. With such unprecedented efficiency, CROs ensure delivery of results that optimize their clients’ market performance and catapult profitability.
Availing themselves of JusGlobal Pharma technology, CRO companies not only exponentially increase demand for their services but increase their bandwidth to accommodate that uptick in business. Achieving shorter study times overall means more CRO clients can be accommodated at once incurring substantive infrastructure costs. In addition, gaining a reputation for simultaneously preserving client capital while advancing market share, empowers a CRO to move to the summit of a highly competitive and crowded marketplace while commanding top fees for its services.

JusGlobal Pharma provides support for CROs that receive investigatory assignments from both large and small or niche pharmaceutical and biotech companies.

The large corporations are typically under pressure to reward shareholders while the smaller niche companies seek to be recognized for speeding to market groundbreaking interventions, becoming ripe targets for extremely profitable acquisitions by a larger corporation.

With JusGlobal Pharma, CRO companies outperform their competition and ensure their own enterprise stability and solvency as well as that of their clients.

The JusGlobal Pharma platform and support is for CRO companies is identical to that which we provide to sponsor pharmaceutical and biotech organizations or military branches operating clinical trial centers. CROs receive the same efficiencies, blockchain technology and security as well as the chat, text and video interfacing capabilities and the Open Forum for all parties to exchange information.

Our CROs receive every single element we deliver to elite multinational corporate sponsors as well as the military branches that operate clinical testing centers. In short JusGlobal Pharma has leveled the playing field for clinical trial innovation.

A CRO implementing JusGlobal Pharma protects and propels its competitive edge and marketability.

A CRO purchasing JusGlobal Pharma invites client confidence that it is managing a clinical trial in the most efficacious and judicious manner available.

A CRO with JusGlobal Pharma ability engenders investor confidence and amplifies its growth and acquisition opportunities, potentially exponentially elevating its market valuation.

For Clinical Trial Participants
Clinical trials can be intimidating and confusing. There are many instructions and conditions. Understanding the protocol, adhering to the program and posing the right inquiries can be challenging. JusGlobal Pharma optimizes the process, making it easier than ever to communicate with researchers and other participants. It puts tools in your hands to keep you fully informed throughout a clinical trial.

Learn More

JusGlobal Pharma delivers a team of experts that assists clinical trial participants throughout the process. We interpret industry jargon and eliminate red tape to provide clarity. We troubleshoot challenges. We connect participants with the right studies – and provide an Open Forum for all parties to ask and answer questions related to the clinical trials process.

Get Started

Sign Up

For Investors
Nearly 1,500 drugs and other therapies go into development each year with 80,000 clinical trials conducted annually in the United States. Fewer than ten percent of these compounds, vaccines and devices advance to the marketplace, thus underscoring a budgetary crisis for the entire clinical trials process that affects profitability and consumer cost. JusGlobal Pharma stems potential clinical trial losses before they have a chance to occur and potentially wreak financial havoc on a pharmaceutical enterprise or other clinical trial sponsor.
JusGlobal Pharma provides a transparency that illuminates challenging issues for trial sponsors, facilitating clear insights that enable early course correction, protecting capital investment and generating shareholder confidence that only the most promising compounds and other potential therapies will advance through each stage of a trial, preserving billions of dollars in capital for the industry and permitting executives, researchers and boards of directors to funnel study dollars only to those investigatory treatments with the highest likelihood of obtaining market approval.

JusGlobal Pharma is the only groundbreaking technology created and serviced by an expert team with over 100 years of combined professional experience that streamlines the clinical trials management process, preserving capital, mitigating risk, protecting enterprise stability and optimizing ROI. It empowers investors to maintain high confidence and ensures the enterprise remains an attractive buy.

Learn More

Get Started

Sign Up

Our Team

JusGlobal Law is the creation of internationally accomplished attorneys, corporate executives, finance and banking authorities, regulatory authors and international business experts. The JusGlobal Advisory Board delivers world-class legal guidance and has legal, regulatory and business experience in international markets spanning North America, Europe, Asia and Australia. Perhaps no other enterprise is as diverse, credible, credentialed and broadly versed in the elements of the law that inform the current world market. Such a perspective is priceless in implementing solutions, delivering service and qualifying the attorneys and law firms invited to offer service through the JusGlobal platform.

Beatrice O'Brien

From the High Courts of England and Australia to top Wall Street firms, Founder, Chairman, and CEO Beatrice O’Brien brings more than 25 years of legal industry experience to the table. Mrs. O’Brien understands the complex nexus of global business and law that only an international lens can provide. Mrs. O’Brien was the first Fiji Indian attorney working at Wall Street law firm Cadwalader Wickersham & Taft.

Born in Suva in the Fiji Islands, Mrs. O’Brien was educated in Australia and became an (attorney) solicitor and barrister in the New South Wales Supreme Court. A facile legal mind has allowed her to develop a diverse depth of practice in litigation, corporate real estate, banking and tax law having worked in the UK and the US on some of the largest reorganization and restructuring cases in corporate history.

Ever the innovator, Mrs. O’Brien founded and leads Attorney Placements International (API), a global legal search, recruitment and consulting firm that facilitates law firm mergers and acquisitions moving entire legal practice groups to new firms and placing partners and associates with high-profile international clients. As an ardent educator, she has created revolutionary programs such as the New York Bar Review Quality Program which assists international attorneys in qualifying their unique skills and experience to practice in the US market.

Now, Beatrice O’Brien, in founding and leading JusGlobal, is introducing technology innovations backed by an assembly of diverse professionals with the highest credentialing to offer unprecedented insight, guidance and security across the legal, pharmaceutical, health care and military clinical trials space. Ms. O’Brien speaks fluent Hindi.

Duane Lakings

Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. He is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He is the principal and president of Texas-based Drug Safety Evaluation, in which he assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.

Dr. Lakings has served as director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York and a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.

Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).

Dr. Lakings holds a PhD, MS and BS from the University of Missouri-Columbia.

Eyal Ron

Dr. Eyal S. Ron adds value for JusGlobal Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.

With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.

He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.

Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.

Oliver Ramsbottom
A Harvard and Oxford graduate, Mr. Ramsbottom is a partner at global management consulting firm McKinsey & Company. He has extensive international business experience, having worked in London, Mainland China and Tokyo for over 25 years. Mr. Ramsbottom’s expertise includes strategy, corporate finance and business development for global enterprises and financial institutions, including private equity firms and sovereign wealth funds. Mr. Ramsbottom speaks fluent Mandarin.
Kathleen McMorrow
As Chief Marketing & Communications Officer, Kathleen R. McMorrow for JusGlobal offering our enterprise a broad yet integrated client-centric view of the marketing and communications process. She oversees brand messaging, market research, business development activities and marketing communications for JusGlobal, and advises our clients in the same pursuits. Under her purview are digital, social, print and broadcast media engagement as well as corporate communications and presentations, speaking engagements and the public appearances of our principals. An accomplished marketer, media and branding expert and corporate storyteller, Ms. McMorrow has specialized knowledge of both the clinical trials industry and the international law firms landscape. She started her post-collegiate career in market research where she conducted intensive B2B studies on behalf of clients such as Standard & Poor’s, A.M. Best and AIG. She next joined a New York public relations firm focused on patient recruitment for clinical drug trials. There, she placed patient-focused stories in the news media coast to coast to attract participants to clinical studies on behalf of clients Janssen and Medtronic. Ms. McMorrow was recruited by renowned media and strategic communications firm Rubenstein, where she became the youngest senior vice president. She managed practice areas in the law firms/business/financial space and global real estate development arena. After more than 15 years in upper management at Rubenstein, she relocated to the west coast to work as managing director of a cultural competency firm serving international corporate clients. She was also a senior counselor at a Los Angeles financial public relations firm delivering strategies for publicly traded and private equity enterprises. Ms. McMorrow graduated magna cum laude from The College of New Jersey and holds a graduate certificate in Public Relations Management from Rutgers University.
Patricia A. Blaine

Patricia A. Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.

Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.

Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).